Capital Research Global Investors Has $196.72 Million Stock Position in IQVIA Holdings Inc. $IQV

Capital Research Global Investors lowered its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 3.2% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 872,634 shares of the medical research company’s stock after selling 28,714 shares during the quarter. Capital Research Global Investors owned 0.51% of IQVIA worth $196,718,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Ameliora Wealth Management Ltd. acquired a new stake in IQVIA in the 4th quarter valued at approximately $25,000. International Assets Investment Management LLC acquired a new stake in IQVIA in the 4th quarter valued at approximately $27,000. Activest Wealth Management grew its holdings in IQVIA by 590.0% in the 4th quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock valued at $31,000 after buying an additional 118 shares during the last quarter. Measured Wealth Private Client Group LLC acquired a new stake in IQVIA in the 3rd quarter valued at approximately $30,000. Finally, Atlantic Union Bankshares Corp acquired a new stake in IQVIA in the 3rd quarter valued at approximately $36,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Price Performance

Shares of NYSE:IQV opened at $183.64 on Tuesday. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.20. The firm has a market capitalization of $30.65 billion, a PE ratio of 22.76, a PEG ratio of 1.57 and a beta of 1.21. IQVIA Holdings Inc. has a 1-year low of $151.58 and a 1-year high of $247.04. The business’s 50 day moving average is $172.42 and its 200-day moving average is $194.55.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, topping the consensus estimate of $2.83 by $0.07. The business had revenue of $4.15 billion during the quarter, compared to the consensus estimate of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.IQVIA’s revenue was up 8.4% on a year-over-year basis. During the same quarter last year, the company earned $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Sell-side analysts predict that IQVIA Holdings Inc. will post 11.6 earnings per share for the current year.

IQVIA declared that its board has approved a stock buyback program on Thursday, May 7th that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the medical research company to reacquire up to 6.8% of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s board of directors believes its shares are undervalued.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on IQV shares. Royal Bank Of Canada started coverage on IQVIA in a report on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 price objective on the stock. Evercore reissued an “outperform” rating and set a $185.00 price objective on shares of IQVIA in a report on Wednesday, April 8th. Truist Financial decreased their price objective on IQVIA from $290.00 to $245.00 and set a “buy” rating on the stock in a report on Thursday, February 19th. Mizuho set a $215.00 price objective on IQVIA in a report on Monday, February 23rd. Finally, Wall Street Zen lowered IQVIA from a “buy” rating to a “hold” rating in a report on Saturday. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $224.13.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.